Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Maju Mathews,1 Srihari Gopal,1 Isaac Nuamah,1 Ludger Hargarter,2 Adam J Savitz,1 Edward Kim,3 Wilson Tan,4 Bernardo Soares,5 Christoph U Correll6–81Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA; 2Department of Neuroscience, Janssen-Cilag EMEA, Ne...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	number-needed-to-harm number-needed-to-treat paliperidone palmitate 3-monthly remission Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b81367fbed5e43a5b09a55d1a775e7bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b81367fbed5e43a5b09a55d1a775e7bc
record_format	dspace
spelling	oai:doaj.org-article:b81367fbed5e43a5b09a55d1a775e7bc2021-12-02T01:24:47ZClinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia1178-2021https://doaj.org/article/b81367fbed5e43a5b09a55d1a775e7bc2019-05-01T00:00:00Zhttps://www.dovepress.com/clinical-relevance-of-paliperidone-palmitate-3-monthly-in-treating-sch-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Maju Mathews,1 Srihari Gopal,1 Isaac Nuamah,1 Ludger Hargarter,2 Adam J Savitz,1 Edward Kim,3 Wilson Tan,4 Bernardo Soares,5 Christoph U Correll6–81Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA; 2Department of Neuroscience, Janssen-Cilag EMEA, Neuss, Deutschland; 3Janssen Scientific Affairs, LLC, Hopewell, NJ, USA; 4Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore; 5Neuroscience Medical Affairs, Janssen-Cilag, High Wycombe, Buckinghamshire, UK; 6The Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, NY, USA; 7Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, East Garden City, NY, USA; 8Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, GermanyAbstract: Antipsychotics are the mainstay in schizophrenia management, and long-acting injectable (LAI) antipsychotics contribute to the successful maintenance of treatment by improving non-adherence and preventing relapses. Paliperidone palmitate 3-monthly (PP3M) formulation is the only available LAI antipsychotic that offers an extended 3-month window of stable plasma drug concentration, enabling only four injections per year. This paper summarizes clinically relevant endpoints from available evidence for PP3M to bridge translational research gaps and provide measurable outcomes that can be interpreted in clinical practice. Low number-needed-to-treat (NNT) for relapse prevention (NNT [95% CI] 6-month estimate: 4.8 [3.2; 10.0]; 12-month estimate: 3.4 [2.2; 7.0]), and high number-needed-to-harm (NNH [95% CI] akathisia, 27.1 [12.3; −667.1]; tremor, 80.0 [22.5; 67.3]; dyskinesia, −132.6 [44.5; −23.2]; parkinsonism, 160.0 [28.9; −49.8]) quantify the relative benefits and low propensity for adverse events with PP3M. Symptom remission and reductions in positive and negative symptoms indicate treatment stability. Additionally, meaningful functional remission, reduced dosing frequency, and freedom from daily negotiations favorably impact patient preference and attenuate burdensome aspects of caregiving, representing important healthcare determinants that enhance prospects of treatment continuity in schizophrenia. This information can potentially improve clinicians’ judgment of treatment choices, clinical response, and patient selection in routine care. Taken together, PP3M is a valuable antipsychotic treatment option, meriting consideration for a broader role in the long-term management of schizophrenia; its utility should not be limited to patients with poor adherence or when oral antipsychotics have failed.Keywords: number-needed-to-harm, number-needed-to-treat, paliperidone palmitate 3-monthly, remissionMathews MGopal SNuamah IHargarter LSavitz AJKim ETan WSoares BCorrell CUDove Medical Pressarticlenumber-needed-to-harmnumber-needed-to-treatpaliperidone palmitate 3-monthlyremissionNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 1365-1379 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	number-needed-to-harm number-needed-to-treat paliperidone palmitate 3-monthly remission Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	number-needed-to-harm number-needed-to-treat paliperidone palmitate 3-monthly remission Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Mathews M Gopal S Nuamah I Hargarter L Savitz AJ Kim E Tan W Soares B Correll CU Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
description	Maju Mathews,1 Srihari Gopal,1 Isaac Nuamah,1 Ludger Hargarter,2 Adam J Savitz,1 Edward Kim,3 Wilson Tan,4 Bernardo Soares,5 Christoph U Correll6–81Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA; 2Department of Neuroscience, Janssen-Cilag EMEA, Neuss, Deutschland; 3Janssen Scientific Affairs, LLC, Hopewell, NJ, USA; 4Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore; 5Neuroscience Medical Affairs, Janssen-Cilag, High Wycombe, Buckinghamshire, UK; 6The Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, NY, USA; 7Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, East Garden City, NY, USA; 8Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, GermanyAbstract: Antipsychotics are the mainstay in schizophrenia management, and long-acting injectable (LAI) antipsychotics contribute to the successful maintenance of treatment by improving non-adherence and preventing relapses. Paliperidone palmitate 3-monthly (PP3M) formulation is the only available LAI antipsychotic that offers an extended 3-month window of stable plasma drug concentration, enabling only four injections per year. This paper summarizes clinically relevant endpoints from available evidence for PP3M to bridge translational research gaps and provide measurable outcomes that can be interpreted in clinical practice. Low number-needed-to-treat (NNT) for relapse prevention (NNT [95% CI] 6-month estimate: 4.8 [3.2; 10.0]; 12-month estimate: 3.4 [2.2; 7.0]), and high number-needed-to-harm (NNH [95% CI] akathisia, 27.1 [12.3; −667.1]; tremor, 80.0 [22.5; 67.3]; dyskinesia, −132.6 [44.5; −23.2]; parkinsonism, 160.0 [28.9; −49.8]) quantify the relative benefits and low propensity for adverse events with PP3M. Symptom remission and reductions in positive and negative symptoms indicate treatment stability. Additionally, meaningful functional remission, reduced dosing frequency, and freedom from daily negotiations favorably impact patient preference and attenuate burdensome aspects of caregiving, representing important healthcare determinants that enhance prospects of treatment continuity in schizophrenia. This information can potentially improve clinicians’ judgment of treatment choices, clinical response, and patient selection in routine care. Taken together, PP3M is a valuable antipsychotic treatment option, meriting consideration for a broader role in the long-term management of schizophrenia; its utility should not be limited to patients with poor adherence or when oral antipsychotics have failed.Keywords: number-needed-to-harm, number-needed-to-treat, paliperidone palmitate 3-monthly, remission
format	article
author	Mathews M Gopal S Nuamah I Hargarter L Savitz AJ Kim E Tan W Soares B Correll CU
author_facet	Mathews M Gopal S Nuamah I Hargarter L Savitz AJ Kim E Tan W Soares B Correll CU
author_sort	Mathews M
title	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
title_short	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
title_full	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
title_fullStr	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
title_full_unstemmed	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
title_sort	clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/b81367fbed5e43a5b09a55d1a775e7bc
work_keys_str_mv	AT mathewsm clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT gopals clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT nuamahi clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT hargarterl clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT savitzaj clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT kime clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT tanw clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT soaresb clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia AT correllcu clinicalrelevanceofpaliperidonepalmitate3monthlyintreatingschizophrenia
_version_	1718403097578962944

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Ejemplares similares